 |
245 Diseases |  |
54 Trials |
|
54 Trials |  |
1419 News |  |
| «12...9101112131415161718192021» |
- Trial primary completion date: High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=174, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jul 2016 --> Oct 2016
- Rituxan (rituximab) / Roche
Trial completion, Enrollment change: High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk (clinicaltrials.gov) - Aug 19, 2016
P2, N=27, Completed, Sponsor: Azienda Ospedaliera Spedali Civili di Brescia
Trial primary completion date: Jul 2016 --> Oct 2016 Active, not recruiting --> Completed | N=43 --> 27
- Trial primary completion date, Gene therapy: Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma (clinicaltrials.gov) - Aug 16, 2016
P=N/A, N=10, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | N=43 --> 27 Trial primary completion date: Jul 2016 --> Jul 2017
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Enrollment closed: NCI-2013-00701: O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (clinicaltrials.gov) - Aug 13, 2016
P1/2, N=24, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jul 2016 --> Jul 2017 Suspended --> Active, not recruiting
- Campath (alemtuzumab) / Sanofi
Trial completion, Metastases: Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 12, 2016
P2, N=30, Completed, Sponsor: German CLL Study Group
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- | Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment closed: SPINOZA: BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin (clinicaltrials.gov) - Aug 9, 2016
P3, N=158, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg., etoposide IV / Generic mfg., carmustine / Generic mfg.
Trial primary completion date: Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (clinicaltrials.gov) - Aug 8, 2016
P=N/A, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> Oct 2017
- || Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant (clinicaltrials.gov) - Aug 8, 2016
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Feb 2017 --> Feb 2018
- Clinical: Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma (clinicaltrials.gov) - Jul 26, 2016
P3, N=442, Terminated, Sponsor: French Innovative Leukemia Organisation
Trial primary completion date: Feb 2017 --> Feb 2018 N=810 --> 442 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Mar 2016; Other new drugs
- Leukine (sargramostim) / Partner Therap
Trial completion: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=4, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=810 --> 442 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Mar 2016; Other new drugs Terminated --> Completed
- | Imbruvica (ibrutinib) / AbbVie, J&J
IO biomarker: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jul 19, 2016
P3, N=302, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Initiation date: Sep 2015 --> Jul 2016
- | Rituxan (rituximab) / Roche
Trial completion: Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 17, 2016
P2, N=79, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Initiation date: Sep 2015 --> Jul 2016 Active, not recruiting --> Completed
- | etoposide oral / Generic mfg., cisplatin / Generic mfg.
Trial completion: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma (clinicaltrials.gov) - Jul 12, 2016
P2, N=29, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 12, 2016
P2, N=36, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed No longer recruiting --> Completed
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 16, 2016
P2, N=101, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
No longer recruiting --> Completed Trial primary completion date: Jul 2016 --> Jul 2017
- Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial initiation date: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies (clinicaltrials.gov) - Jun 15, 2016
P1, N=44, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jul 2016 --> Jul 2017 Initiation date: Apr 2016 --> Sep 2016
- Starasid (cytarabine ocfosfate) / Nippon Kayaku
New P1/2 trial, Gene therapy: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (clinicaltrials.gov) - Jun 13, 2016
P1/2, N=18, Recruiting, Sponsor: AIDS Malignancy Consortium
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Jun 11, 2016
P2, N=40, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Apr 2016 --> Sep 2016 N=20 --> 40
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Trial initiation date: HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection (clinicaltrials.gov) - Jun 5, 2016
P1, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=20 --> 40 Initiation date: Mar 2016 --> Sep 2016
- New P2 trial, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Jun 2, 2016
P2, N=20, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- vadacabtagene leraleucel (JCAR015) / BMS
Enrollment closed: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 27, 2016
P1, N=17, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Mar 2016 --> Sep 2016 Recruiting --> Active, not recruiting
- || Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci, Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial primary completion date: CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies (clinicaltrials.gov) - Apr 7, 2016
P1, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- temozolomide / Generic mfg.
Trial primary completion date: DRBEAT: The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma (clinicaltrials.gov) - Apr 7, 2016
P2, N=20, Recruiting, Sponsor: Cedars-Sinai Medical Center
Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- vadacabtagene leraleucel (JCAR015) / BMS
Trial primary completion date: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 7, 2016
P1, N=18, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Apr 2016 --> Apr 2017
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Trial suspension: NCI-2013-00701: O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (clinicaltrials.gov) - Mar 30, 2016
P1/2, N=24, Suspended, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Apr 2016 --> Apr 2017 Recruiting --> Suspended
- Trial primary completion date: Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Feb 29, 2016
P2, N=20, Recruiting, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Recruiting --> Suspended Trial primary completion date: Nov 2016 --> Nov 2017
- | Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Trial completion: Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma (clinicaltrials.gov) - Feb 27, 2016
P3, N=427, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: Nov 2016 --> Nov 2017 Active, not recruiting --> Completed
- | Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial initiation date, Trial primary completion date: FIL FLAZ12: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (clinicaltrials.gov) - Feb 26, 2016
P3, N=265, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Jan 2012 | Trial primary completion date: Jan 2016 --> Mar 2017
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment change, Trial primary completion date: Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation (clinicaltrials.gov) - Feb 21, 2016
P2, N=50, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jun 2012 --> Jan 2012 | Trial primary completion date: Jan 2016 --> Mar 2017 N=30 --> 50 | Trial primary completion date: Nov 2016 --> Nov 2017
- New P2 trial: Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Feb 1, 2016
P2, N=20, Recruiting, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- cyclophosphamide / Generic mfg., etoposide IV / Generic mfg., carmustine / Generic mfg.
Trial primary completion date: Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (clinicaltrials.gov) - Jan 30, 2016
P=N/A, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
N=30 --> 50 | Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: May 2016 --> Oct 2016
- Trial primary completion date: Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 25, 2016
P2, N=325, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: May 2016 --> Oct 2016 Trial primary completion date: Dec 2015 --> Jan 2018
- | Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date: NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse (clinicaltrials.gov) - Jan 22, 2016
P2, N=20, Recruiting, Sponsor: University of California, Davis
Trial primary completion date: Dec 2015 --> Jan 2018 Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial primary completion date, IO biomarker: Autologous Transplant in HIV Patients (BMT CTN 0803) (clinicaltrials.gov) - Jan 18, 2016
P2, N=40, Active, not recruiting, Sponsor: Medical College of Wisconsin
Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016 Trial primary completion date: Nov 2015 --> May 2015
- cyclophosphamide / Generic mfg., carmustine / Generic mfg.
Trial primary completion date: Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 17, 2016
P3, N=352, Recruiting, Sponsor: Vastra Gotaland Region
Trial primary completion date: Nov 2015 --> May 2015 Trial primary completion date: Sep 2015 --> Aug 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study (clinicaltrials.gov) - Jan 16, 2016
P2, N=25, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Sep 2015 --> Aug 2016 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk (clinicaltrials.gov) - Jan 7, 2016
P2, N=43, Active, not recruiting, Sponsor: Azienda Ospedaliera Spedali Civili di Brescia
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2012 --> May 2016
- Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma (clinicaltrials.gov) - Jan 7, 2016
P2, N=7, Completed, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2012 --> May 2016 Active, not recruiting --> Completed | N=20 --> 7 | Trial primary completion date: Jul 2014 --> Dec 2015
- Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial initiation date: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies (clinicaltrials.gov) - Dec 15, 2015
P1, N=44, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=20 --> 7 | Trial primary completion date: Jul 2014 --> Dec 2015 Initiation date: Sep 2015 --> Apr 2016
- | Imbruvica (ibrutinib) / AbbVie, J&J
IO biomarker: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Dec 15, 2015
P3, N=302, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Sep 2015 --> Apr 2016 Initiation date: May 2016 --> Sep 2015
- | Imbruvica (ibrutinib) / AbbVie, J&J
IO biomarker: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Dec 14, 2015
P3, N=302, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: May 2016 --> Sep 2015 Initiation date: Sep 2015 --> May 2016
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Trial initiation date: HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection (clinicaltrials.gov) - Dec 4, 2015
P1, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Sep 2015 --> May 2016 Initiation date: Jun 2015 --> Mar 2016
- melphalan / Generic mfg., cytarabine / Generic mfg., carmustine / Generic mfg.
Enrollment open, Trial initiation date: A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) (clinicaltrials.gov) - Nov 27, 2015
P2, N=98, Recruiting, Sponsor: University Hospital Inselspital, Berne
Initiation date: Jun 2015 --> Mar 2016 Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Apr 2015
- | carmustine / Generic mfg.
Trial completion: Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Nov 16, 2015
P1/2, N=40, Completed, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Apr 2015 Active, not recruiting --> Completed
- Enrollment closed: Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov) - Nov 10, 2015
P1/2, N=80, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (clinicaltrials.gov) - Nov 5, 2015
P2, N=50, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2015
- Trial primary completion date, Gene therapy: Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=10, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2015 Trial primary completion date: Dec 2015 --> Jul 2016
- Simulect (basiliximab) / Novartis, 90Y basiliximab - National Cancer Institute / Bethesda
Phase classification: Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov) - Oct 22, 2015
P1, N=22, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Dec 2015 --> Jul 2016 Phase classification: P1/2 --> P1
- | New P2 trial: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Oct 7, 2015
P2, N=150, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 1, 2015
P2, N=20, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Phase classification: P1/2 --> P1 Recruiting --> Active, not recruiting